These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27922482)

  • 21. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer.
    Grant KA; Pienaar FM; Brundyn K; Swart G; Gericke GS; Myburgh EJ; Wright CA; Apffelstaedt JP; Kotze MJ
    Breast; 2015 Apr; 24(2):137-42. PubMed ID: 25586984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
    Borczuk AC; Allen TC
    Arch Pathol Lab Med; 2016 Apr; 140(4):351-4. PubMed ID: 26756646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
    Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
    Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Consortium for Analytic Standardization in Immunohistochemistry.
    Bogen SA; Dabbs DJ; Miller KD; Nielsen S; Parry SC; Szabolcs MJ; t'Hart N; Taylor CR; Torlakovic EE
    Arch Pathol Lab Med; 2022 May; 147(5):584-590. PubMed ID: 36084252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
    Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
    J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opinion: redefining the role of the physician in laboratory medicine in the context of emerging technologies, personalised medicine and patient autonomy ('4P medicine').
    Orth M; Averina M; Chatzipanagiotou S; Faure G; Haushofer A; Kusec V; Machado A; Misbah SA; Oosterhuis W; Pulkki K; Twomey PJ; Wieland E
    J Clin Pathol; 2019 Mar; 72(3):191-197. PubMed ID: 29273576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
    Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics.
    Elliott K; McQuaid S; Salto-Tellez M; Maxwell P
    J Clin Pathol; 2015 Oct; 68(10):766-70. PubMed ID: 26280782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Audit of Failed Immunohistochemical Slides in a Clinical Laboratory: The Role of On-Slide Controls.
    Cheung CC; Taylor CR; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2017; 25(5):308-312. PubMed ID: 26657875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry in the era of personalised medicine.
    McCourt CM; Boyle D; James J; Salto-Tellez M
    J Clin Pathol; 2013 Jan; 66(1):58-61. PubMed ID: 23002284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
    Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV
    Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. General Guidelines for Quality Assurance of Immunohistochemistry in a Mohs Lab.
    Kinas CG; Carroll BT
    Dermatol Surg; 2017 Apr; 43(4):507-511. PubMed ID: 28359076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.
    Cheung CC; Garratt J; Won J; Cutz JC; Gilks BC; Tsao M; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2015; 23(10):677-81. PubMed ID: 26551338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
    Kerr KM; Tsao MS; Nicholson AG; Yatabe Y; Wistuba II; Hirsch FR;
    J Thorac Oncol; 2015 Jul; 10(7):985-9. PubMed ID: 26134220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
    Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
    Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.